Time-Course of Nigrostriatal Degeneration in a Progressive MPTP-Lesioned Macaque Model of Parkinson's Disease

Molecular Neurobiology

Volumn 28, Issue 3, 2003, Pages 209-218

  Meissner, Wassilios ^a   Prunier, Caroline ^b   Guilloteau, Denis ^b   Chalon, Sylvie ^b   Gross, Christian E ^a   Bezard, Erwan ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

Author keywords

Chronic MPTP model; Kinetics of nigral degeneration; Striatum; Substantia nigra; Threshold for symptom appearance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

CLINICAL FEATURE; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACACA; MONKEY; NERVE CELL; NONHUMAN; PARKINSON DISEASE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION;

EID: 0742269622     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:28:3:209     Document Type: Review

References (52)

1. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., and Kopin I.J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of MPTP. Life Sci. 39, 7-16.
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455.
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci. 3, 1306-1312.
4. Bezard E., Boraud T., Bioulac B., and Gross C. (2000) Evolution of the multiunit activity of basal ganglia in the course of a dynamic experimental parkinsonism, in The Basal ganglia VI (Graybiel A., ed.), Kluwer Academic Publishers, Norwell, 2001, pp. 107-116.
5. Bezard E., Crossman A.R., Gross C.E., and Brotchie J.M. (2001a) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB J. 10.1096, 1092-1094.
6. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., et al. (2001b) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861.
7. Bezard E. and Gross C.E. (1998) Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55, 93-116.
8. Bezard E., Imbert C., Deloire X., Bioulac B., and Gross C. (1997) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766, 107-112.
9. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., and Brotchie J.M. (2001c) Upregulation of Striatal Preproenkephalin Gene Expression Occurs Before the Appearance of Parkinsonian Signs in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine Monkeys. Neurobiol. Dis. 8, 343-350.
10. Brooks D.J., Ibanez V., Sawle G.V., Quinn N., Lees A.J., Mathias C.J., et al. (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 28, 547-555.
11. Calne D.B. (1994) Is idiopathic Parkinsonism the consequence of an event or a process? Neurology 44, 5-10.
12. Chiueh C.C., Burns R.S., Markey S.P., Jacobowitz D.M., and Kopin I.J. (1985) Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci. 36, 213-218.
13. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. (1999a) The substantia nigra of the human brain - I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry. Brain 122, 1421-1436.
14. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. (1999b) The substantia nigra of the human brain - II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122, 1437-1448.
15. Ehringer H. and Hornykiewicz O. (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38, 1236-1239.
16. Elsworth J.D., Taylor J.R., Sladek J.R., Collier T.J., Redmond D.E., and Roth R.H. (2000) Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in Old-World primates one year after MPTP treatment. Neuroscience 95, 399-408.
17. Fearnley J.M. and Lees A.J. (1991) Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
18. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325.
19. German D.C., Dubach M., Askari S., Speciale S.G., and Bowden D.M. (1988b) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174.
20. German D.C., Dubach M., Askari S., Speciale S.G., and Bowden D.M. (1988a) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis : which midbrain dopaminergic neurons are lost? Neuroscience 24, 161-174.
21. German D.C., Nelson E.L., Liang C.-L., Speciale S.G., Sinton C.M., and Sonsalla P.K. (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9, and AlO dopaminergic neurons in the mouse. Neurodegeneration 5, 299-312.
22. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., and Bezard E. (2003) Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84, 1246-1255.
23. Hantraye P., Varastet M., and Peschanski M. (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53, 169-178.
24. Hassler R. (1938) Zur Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48, 387-476.
25. Hirsch E.C. (1999) Mechanism and consequences of nerve cell death in Parkinson's disease. J. Neural Transm. - Suppl. 127-137.
26. Hirsch E.C., Graybiel A.M., and Agid Y. (1988) Melanized dopaminergic neurons are differentially affected in Parkinson's disease. Nature 334, 345-348.
27. Hirsch E.C., Hunot S., Damier P., and Faucheux B. (1998) Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44, S115-S120.
28. Hoehn H.M. and Yahr M.D. (1967) Parkinsonism: onset, progression and mortality. Neurology 17, 427-442.
29. Höglinger G.U., Féger J., Pringent A., Michel P.P., Parain K., Champy P., et al. (2003) Chronic systemic complex I inhibition icduces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491-502.
30. Hornykiewicz O. and Kish S.J. (1987) Biochemical pathophysiology of Parkinson's disease, in Parkinson's disease (Yahr M. and Bergmann K.J., eds.), pp. 19-34. Raven Press, New York.
31. Irwin I., DeLanney L.E., Forno L.S., Finnegan K.T., DiMonte D.A., and Langston J.W. (1990) The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res. 531, 242-252.
32. Kish S.J., Shannak K., and Hornykiewicz O. (1988) Uneven pattern of dopamine loss in the striarum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880.
33. Koller W.C., Langston J.W., Hubble J.P., Irwin I., Zack M., Golbe L., et al. (1991) Does a long pre-clinical period occur in Parkinson's disease? Neurology 41, 8-13.
34. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211-213.
35. Langston J.W., Ballard P., Tetrud J., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analogsynthesis. Science 219, 979-980.
36. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598-605.
37. Lee C.S., Schulzer M., Mak E.K., Snow B.J., Tsui J.K., Calne S., et al. (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117, 501-507.
38. McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24, 574-576.
39. Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., and Graybiel A.M. (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad Sci. USA 89, 3859-3863.
40. 18F]dopa- PET and clinical study of the rate of progression in Parkinson's disease. Brain 119, 585-591.
41. Parkinson J. (1817) An essay on the Shaking Palsy, Sherwood, Nelly and Jones, London.
42. Perez-Otano I., Oset C., Luquin M.R., Herrero M.T., Obeso J.A., and Del Rio J. (1994) MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci. Lett. 175, 121-125.
43. 123I-PE21 SPECT. Neuroimage in press.
44. Raff M.C., Whitmore A.V., and Finn J.T. (2002) Axonal self-destruction and neurodegeneration. Science 296, 868-871.
45. Riederer P. and Wuketich S. (1976) Time course of nigrostriatal degeneration in parkinson's disease. J. Neural Transm. 38, 277-301.
46. Schneider J.S. (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res. 534, 25-36.
47. Schneider J.S., Decamp E., and Wade T. (1999) Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatololgy. J. Neurosci. 19, 6643-6649.
48. Schneider J.S. and Kovelowski C.J. (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. Brain Res. 519, 122-128.
49. Schulzer M., Lee C.S., Mak E.K., Vingerhoets F.J.G., and Calne D.B. (1994) A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 117, 509-516.
50. Snow B.J., Vingerhoets F.J.G., Langston J.W., Tetrud J.W., Sossi V., and Calne D.B. (2000) Pattern of dopaminergic loss in the striarum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 68, 313-316.
51. Varastet M., Riche D., Mazière M., and Hantraye P. (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63, 47-56.
52. Vingerhoets F.J.G., Snow B.J., Lee C.S., Schulzer M., Mak E., and Calne D.B. (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 36, 759-764.